To learn more about Scribe’s mission to engineer the future of genetic medicine, visit View source version on businesswire. Rowe Price Associates, Inc., funds managed by Wellington Management, RA Capital Management, and Menlo Ventures. The company is backed by leading individual and institutional investors including Andreessen Horowitz, Avoro Ventures and Avoro Capital Advisors, OrbiMed Advisors, Perceptive Advisors, funds and accounts advised by T. Scribe is molecular engineering the most advanced platform for CRISPR-based genetic medicine. Founded by CRISPR inventors and leading molecular engineers Benjamin Oakes, Brett Staahl, David Savage, and Jennifer Doudna, Scribe is overcoming the limitations of current genome editing technologies by developing custom engineered enzymes and delivery modalities as part of a proprietary, evergreen CRISPR by Design™ platform for genetic medicine. Scribe Therapeutics is a molecular engineering company focused on creating best-in-class in vivo therapies that permanently treat the underlying cause of disease. "This collaboration with Scribe complements our robust research efforts across the NK cell therapy spectrum and offers our scientists unique access to engineered CRISPR-based technologies as they strive to deliver off-the-shelf NK cell therapies and novel combination approaches that improve upon the first generation of cell therapies." "At Sanofi, we are pushing the boundaries of science by developing a diverse range of next-generation therapies based on natural killer (NK) cells, which could have broad applications across solid tumors and blood cancers," said Frank Nestle, Global Head of Research and Chief Scientific Officer, Sanofi. "Scribe is proud to expand the use of our XE CRISPR technologies with the team at Sanofi, whose commitment to deep scientific rigor and clinical development experience will enable the rapid advancement of novel ex vivo cell therapies for patients in need." Scribe Therapeutics Stanford Continuing Studies About Experienced Translational Medicine Scientist and Team Leader with a successful history of working in the biotechnology industry developing. Scribe Therapeutics is a molecular engineering company focused on creating best-in-class in vivo therapies that permanently treat the underlying cause of. Rowe Price are the most recent investors. Scribe Therapeutics is funded by 9 investors. Their latest funding was raised on from a Series B round. "We’re pleased to provide Sanofi with access to Scribe’s proprietary and enhanced gene editing technologies for use in ex vivo oncology applications distinct from our current pipeline," said Benjamin Oakes, Ph.D., co-founder and CEO of Scribe. Scribe Therapeutics has raised a total of 120M in funding over 2 rounds. Scribe’s suite of custom engineering genome editing and delivery tools called CasX-Editors (XE), based on novel foundations such as the CasX enzyme, will support Sanofi’s expanding pipeline of NK cell therapeutics for oncology. The agreement grants Sanofi non-exclusive rights to Scribe’s proprietary CRISPR platform of wholly owned enzymes to create ex vivo NK cell therapies. Scribe to grant Sanofi non-exclusive license to genome editing CasX-Editor (XE) technology for multiple oncology targets in exchange for a $25 million upfront fee with the potential for more than $1 billion in milestone payments, and tiered royaltiesĪLAMEDA, Calif., September 27, 2022-( BUSINESS WIRE)-Scribe Therapeutics Inc., a molecular engineering company pioneering a CRISPR by Design™ platform for genetic medicine, today announced a strategic collaboration with Sanofi for the use of Scribe’s CRISPR genome editing technologies to enable genetic modification of novel natural killer (NK) cell therapies for cancer. To learn more about Scribe’s mission to engineer the future of genetic medicine, visit View source version on businesswire.Sanofi selects Scribe’s CRISPR by Design™ platform to enable oncology pipeline of engineered natural killer (NK) cell therapies Join to view profile Scribe Therapeutics. Rowe Price Associates, Inc., funds managed by Wellington Management, RA Capital Management, and Menlo Ventures. Scientist at Scribe Therapeutics San Francisco, California, United States. The company is backed by leading individual and institutional investors including Andreessen Horowitz, Avoro Ventures and Avoro Capital Advisors, OrbiMed Advisors, Perceptive Advisors, funds and accounts advised by T.
0 Comments
Leave a Reply. |